Erratum: Modulation of Host Angiogenesis as a Microbial Survival Strategy and Therapeutic Target (PLoS Pathogens (2016) 12:4 (e1005479) DOI: 10.1371/journal.ppat.1005479);Modulation of Host Angiogenesis as a Microbial Survival Strategy and Therapeutic Target

PLoS Pathogens

Volumn 12, Issue 4, 2016, Pages

  Osherov, Nir ^a   Ben Ami, Ronen ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBROBLAST GROWTH FACTOR; FLICE INHIBITORY PROTEIN; G PROTEIN COUPLED RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LACTIC ACID; MICRORNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ANGIOGENIC FACTOR;

ANGIOGENESIS; BLOOD VESSEL; CELL MIGRATION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFECTION; INTRACELLULAR SIGNALING; METABOLITE; MICROBIAL SURVIVAL; MICROBIAL VIABILITY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TYPE IV SECRETION SYSTEM; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; NEOVASCULARIZATION (PATHOLOGY); ORGANISMAL INTERACTION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; HOST-PATHOGEN INTERACTIONS; HUMANS; INFECTION; MICROBIAL INTERACTIONS; MICROBIAL VIABILITY; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84964887761     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005838     Document Type: Erratum

References (43)

1. Carmeliet P, Jain RK, Molecular mechanisms and clinical applications of angiogenesis. Nature2011;473: 298–307. doi: 10.1038/nature1014421593862
2. Carmeliet P, Angiogenesis in life, disease and medicine. Nature2005;438: 932–936. 16355210
3. Jain RK, Duda DG, Clark JW, Loeffler JS, Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol2006;3: 24–40. 16407877
4. Pinhal-Enfield G, Ramanathan M, Hasko G, Vogel SN, Salzman AL, et al. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors. Am J Pathol2003;163: 711–721. 12875990
5. Ben-Ami R, Angiogenesis at the mold-host interface: a potential key to understanding and treating invasive aspergillosis. Future Microbiol2013;8: 1453–1462. doi: 10.2217/fmb.13.11424199803
6. Datta M, Via LE, Kamoun WS, Liu C, Chen W, et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci U S A2015;112: 1827–1832. doi: 10.1073/pnas.142456311225624495
7. Ben-Ami R, Albert ND, Lewis RE, Kontoyiannis DP, Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. J Infect Dis2013;207: 1066–1074. doi: 10.1093/infdis/jis94023303813
8. Saadi S, Wrenshall LE, Platt JL, Regional manifestations and control of the immune system. FASEB J2002;16: 849–856. 12039867
9. Aird WC, The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood2003;101: 3765–3777. 12543869
10. Bruick RK, McKnight SL, A conserved family of prolyl-4-hydroxylases that modify HIF. Science2001;294: 1337–1340. 11598268
11. Fitzpatrick SF, Tambuwala MM, Bruning U, Schaible B, Scholz CC, et al. An intact canonical NF-kappaB pathway is required for inflammatory gene expression in response to hypoxia. J Immunol2011;186: 1091–1096. doi: 10.4049/jimmunol.100225621149600
12. Taylor CT, Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol2008;586: 4055–4059. doi: 10.1113/jphysiol.2008.15766918599532
13. Werth N, Beerlage C, Rosenberger C, Yazdi AS, Edelmann M, et al. Activation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogens. PLoS ONE2010;5: e11576. doi: 10.1371/journal.pone.001157620644645
14. Hartmann H, Eltzschig HK, Wurz H, Hantke K, Rakin A, et al. Hypoxia-independent activation of HIF-1 by enterobacteriaceae and their siderophores. Gastroenterology2008;134: 756–767. doi: 10.1053/j.gastro.2007.12.00818325389
15. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell2003;112: 645–657. 12628185
16. Siamer S, Dehio C, New insights into the role of Bartonella effector proteins in pathogenesis. Curr Opin Microbiol2015;23: 80–85. doi: 10.1016/j.mib.2014.11.00725461577
17. Gramolelli S, Schulz TF, The role of Kaposi sarcoma-associated herpesvirus in the pathogenesis of Kaposi sarcoma. J Pathol2015;235: 368–380. doi: 10.1002/path.444125212381
18. Cavallin LE, Goldschmidt-Clermont P, Mesri EA, Molecular and cellular mechanisms of KSHV oncogenesis of Kaposi's sarcoma associated with HIV/AIDS. PLoS Pathog2014;10: e1004154. doi: 10.1371/journal.ppat.100415425010730
19. Oehlers SH, Cronan MR, Scott NR, Thomas MI, Okuda KS, et al. Interception of host angiogenic signalling limits mycobacterial growth. Nature2015;517: 612–615. doi: 10.1038/nature1396725470057
20. Ben-Ami R, Lewis RE, Kontoyiannis DP, Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. Br J Haematol2010;150: 406–417. doi: 10.1111/j.1365-2141.2010.08283.x20618330
21. Kamai Y, Chiang LY, Lopes Bezerra LM, Doedt T, Lossinsky AS, et al. Interactions of Aspergillus fumigatus with vascular endothelial cells. Med Mycol2006;44Suppl 1: S115–117. 17050430
22. Shibuya K, Ando T, Hasegawa C, Wakayama M, Hamatani S, et al. Pathophysiology of pulmonary aspergillosis. J Infect Chemother2004;10: 138–145. 15290452
23. Willger SD, Puttikamonkul S, Kim KH, Burritt JB, Grahl N, et al. A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS Pathog2008;4: e1000200. doi: 10.1371/journal.ppat.100020018989462
24. Ben-Ami R, Lewis RE, Leventakos K, Kontoyiannis DP, Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood2009;114: 5393–5399. doi: 10.1182/blood-2009-07-23120919843884
25. Ben-Ami R, Albert ND, Lewis RE, Kontoyiannis DP, Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. J Infect Dis2013.
26. Carmeliet P, Jain RK, Angiogenesis in cancer and other diseases. Nature2000;407: 249–257. 11001068
27. Jain RK, Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell2014;26: 605–622. doi: 10.1016/j.ccell.2014.10.00625517747
28. Brown GD, Denning DW, Levitz SM, Tackling human fungal infections. Science2012;336: 647. doi: 10.1126/science.122223622582229
29. Zumla A, Raviglione M, Hafner R, von Reyn CF, Tuberculosis. N Engl J Med2013;368: 745–755. doi: 10.1056/NEJMra120089423425167
30. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med2002;347: 408–415. 12167683
31. van der Linden JW, Arendrup MC, Warris A, Lagrou K, Pelloux H, et al. Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus. Emerg Infect Dis2015;21: 1041–1044. doi: 10.3201/eid2106.14071725988348
32. O'Rourke F, Mandle T, Urbich C, Dimmeler S, Michaelis UR, et al. Reprogramming of myeloid angiogenic cells by Bartonella henselae leads to microenvironmental regulation of pathological angiogenesis. Cell Microbiol2015;17(10):1447–63. doi: 10.1111/cmi.1244725857345
33. Dehio C, Infection-associated type IV secretion systems of Bartonella and their diverse roles in host cell interaction. Cell Microbiol2008;10: 1591–1598. doi: 10.1111/j.1462-5822.2008.01171.x18489724
34. Ashman RB, Papadimitriou JM, Endothelial cell proliferation associated with lesions of murine systemic candidiasis. Infect Immun1994;62: 5151–5153. 7523305
35. Barker KS, Park H, Phan QT, Xu L, Homayouni R, et al. Transcriptome profile of the vascular endothelial cell response to Candida albicans. J Infect Dis2008;198: 193–202. doi: 10.1086/58951618500935
36. MacManiman JD, Meuser A, Botto S, Smith PP, Liu F, et al. Human cytomegalovirus-encoded pUL7 is a novel CEACAM1-like molecule responsible for promotion of angiogenesis. MBio2014;5: e02035. doi: 10.1128/mBio.02035-1425352622
37. Hassan M, Selimovic D, El-Khattouti A, Soell M, Ghozlan H, et al. Hepatitis C virus-mediated angiogenesis: molecular mechanisms and therapeutic strategies. World J Gastroenterol2014;20: 15467–15475. doi: 10.3748/wjg.v20.i42.1546725400432
38. Tomao F, Papa A, Rossi L, Zaccarelli E, Caruso D, et al. Angiogenesis and antiangiogenic agents in cervical cancer. Onco Targets Ther2014;7: 2237–2248. doi: 10.2147/OTT.S6828625506227
39. Dennis RD, Schubert U, Bauer C, Angiogenesis and parasitic helminth-associated neovascularization. Parasitology2011;138: 426–439. doi: 10.1017/S003118201000164221232174
40. Kanse SM, Liang O, Schubert U, Haas H, Preissner KT, et al. Characterisation and partial purification of Schistosoma mansoni egg-derived pro-angiogenic factor. Molecular and Biochemical Parasitology2005;144: 76–85. 16169609
41. Loeffler DA, Lundy SK, Singh KP, Gerard HC, Hudson AP, et al. Soluble egg antigens from Schistosoma mansoni induce angiogenesis-related processes by up-regulating vascular endothelial growth factor in human endothelial cells. J Infect Dis2002;185: 1650–1656. 12023772
42. Rogers MS, Christensen KA, Birsner AE, Short SM, Wigelsworth DJ, et al. Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth. Cancer Res2007;67: 9980–9985. 17942931
43. Vasil ML, Stonehouse MJ, Vasil AI, Wadsworth SJ, Goldfine H, et al. A complex extracellular sphingomyelinase of Pseudomonas aeruginosa inhibits angiogenesis by selective cytotoxicity to endothelial cells. PLoS Pathog2009;5: e1000420. doi: 10.1371/journal.ppat.100042019424430